What is behind Injective recent drop in value today

Traders Union
All News
Crypto
Injective slides 10.06% today

Highlights

Injective completed key ecosystem upgrades and attracted institutional interest, including a $2 million purchase and new validator from Korea University.
Trading volume for INJ surged 155% to $155.4 million, but price remains under broad selling pressure despite heightened participation.
INJ trades at $2.92, well below major moving averages, with critical support at $2.89 and bearish momentum pointing toward a possible further decline to $2.09.

Ecosystem growth and institutional inflows offset by prevailing selling pressure

Injective completed significant ecosystem upgrades and attracted increased institutional participation with a $2 million purchase. Korea University launched its first enterprise validator and staked 369,809 INJ. Trading volume surged by 155% to $155.4 million, reflecting heightened activity, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Injective’s position below the MA-20, MA-50, and MA-200 as a clear indication of entrenched bearish pressure. He notes heavy selling persists despite increased institutional participation and higher trading volumes, with momentum and trend indicators reinforcing a dominant negative trend. Kharitonov is skeptical about any near-term recovery, highlighting that both the lack of oversold signals on the daily RSI and the position relative to technical resistance ($3.34) limit rebound chances. He cautions that failure at current support levels could trigger further sharp declines and warns that a sideways consolidation is the best-case scenario unless buyers step in decisively. "The technical setup remains weak and investors should avoid catching falling knives until robust reversal signals emerge," Kharitonov advises.

Viktoras Karapetjanc, expert at Traders Union, emphasizes the active institutional interest and major ecosystem developments surrounding Injective. He believes that a $2 million institutional purchase and Korea University’s large-scale staking reinforce a constructive long-term narrative. Karapetjanc views the recent surge in trading volume as a sign of deepening engagement, hinting at future momentum once current headwinds subside. In his view, structural foundations remain intact, and the market is presenting new setups for forward-looking participants. "Further growth is expected in the mid-term as innovative partnerships and institutional flows continue to build market confidence," Karapetjanc asserts.

Parshwa Turakhiya, analyst, assesses Injective with a focus on recent sentiment and price action. He highlights the intense volatility and sharp drop to near-session lows, seeing value for capital-protective traders in monitoring the $2.89 and $2.09 support levels for short-term reaction trades. Turakhiya notes the absence of a clear daily oversold signal but acknowledges tactical opportunities if momentum shifts quickly on lower timeframes. He points out that a decisive break above $3.34 could trigger rapid sentiment reversal. "Short-term traders should stay flexible and watch for a capitulation spike or reversal near oversold levels," Turakhiya notes.

Downside momentum entrenched as indicators confirm high volatility and pressure

On the daily chart, the nearest dynamic resistance is the Ichimoku Kijun at $3.34, while support sits near today’s low of $2.89. The asset is positioned well below all major moving averages, indicating entrenched short-, medium-, and long-term downside pressure. Momentum indicators are aligned with a bearish outlook: the MACD shows strong downside momentum, the ADX points to an established negative trend, and BBP signals dominant seller activity intraday. RSI and Stochastic RSI show no clear oversold signal on the daily timeframe, although both W1 and lower timeframes indicate oversold conditions. The CCI is in the neutral-to-oversold range, and the Awesome Oscillator confirms the prevailing downtrend. Trading today was marked by heavy pressure after the open and high volatility, with the price now near the session low.

Last time, analysts noted that Injective traded just above its weekly MA-20 amid ongoing medium- and long-term selling pressure, with technical indicators such as MACD and RSI remaining bearish and the RSI at 41.26 reflecting continued weakness. Resistance is seen near $3.38, support near the MA-20, and analysts expect limited upside in the near term with consolidation likely within the $2.93–$3.57 range barring a decisive break above resistance.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.